Loading
Most new cancer imaging agents and radioactive drugs start in university hospitals. A network sharing production, quality files and regulatory paperwork would get them into multi-centre trials years faster.
Academic radiopharmacy has repeatedly produced the agents the field now runs on (PSMA ligands and FAPI tracers from Heidelberg, DOTATATE from Basel and Rotterdam) but each centre re-creates production, quality control and regulatory documentation. A funded network of university cyclotrons and radiopharmacies would share drug master files, validated synthesis modules, GMP quality systems and a common clinical trial application template, so a tracer validated in one centre can be adopted in ten within months. It would also provide isotope purchasing at scale (gallium-68 generators, lutetium-177, actinium-225 allocation) for academic trials.
Shares Frederik Giesel, Uwe Haberkorn, Heidelberg University Hospital / NCT / DKFZ, FAPI PET.
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, FAPI PET, PSMA PET.
Shares Michael Hofman, Peter MacCallum Cancer Centre, PSMA PET, Radioligand therapy (beta emitters).
Shares Uwe Haberkorn, FAP theranostics as a pan-cancer stromal strategy, Radiopharmaceutical roadmap: iodine → lutetium → actinium, FAPI PET.
Shares FAP theranostics as a pan-cancer stromal strategy, FAPI PET, Radioligand therapy (beta emitters).
Shares Frederik Giesel, Uwe Haberkorn, FAP theranostics as a pan-cancer stromal strategy, Heidelberg University Hospital / NCT / DKFZ.
Shares Michael Hofman, Peter MacCallum Cancer Centre, PSMA PET.
Shares Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).